SS-31 (Elamipretide): The Mitochondrial Protector

SS-31, known as elamipretide in drug development, is a small synthetic peptide that targets the inner membrane of mitochondria and binds a lipid called cardiolipin, helping stabilize the machinery cells use to produce energy. In September 2025, the FDA granted it accelerated approval, as Forzinity, for Barth syndrome, a rare inherited mitochondrial disease. It is not approved for aging, fatigue or performance, and evidence for those uses is largely limited to animal studies.

What Is SS-31 Elamipretide?

SS-31 is a tetrapeptide, a chain of just four amino acids, designed with an unusual alternating pattern of positive charges and aromatic rings. That structure lets it cross cell membranes and accumulate in the inner mitochondrial membrane, rather than simply circulating in the blood. It has been studied under several names over the years, including SS-31, MTP-131, Bendavia and elamipretide.

Unlike most peptides discussed in longevity circles, SS-31 went through a formal pharmaceutical development program, with randomized human trials across several diseases. That history gives us more reliable safety information than we have for many investigational peptides, and also a clearer picture of where it did and did not work.

How It Works: Cardiolipin and the Energy Machinery

Mitochondria generate most of the cell's usable energy through the electron transport chain, a series of protein complexes embedded in the inner mitochondrial membrane. Those complexes depend on cardiolipin, a specialized phospholipid found almost exclusively in that membrane. Cardiolipin:

• Helps hold the electron transport complexes together in efficient groupings
• Shapes the folded inner membrane (the cristae) where energy production happens
• Anchors cytochrome c, which shuttles electrons between complexes

When cardiolipin is oxidized or abnormal, energy production becomes less efficient and more electrons "leak," generating reactive oxygen species. That can create a cycle of further damage.

SS-31 binds cardiolipin and appears to stabilize it. In laboratory and animal studies, this has been associated with:

• Better-preserved cristae structure
• More efficient ATP (energy) production
• Reduced reactive oxygen species generation
• Less release of cytochrome c, a signal that can trigger cell death

What the Human Evidence Shows

The human trials tell a mixed and instructive story.

• Barth syndrome: This rare genetic condition disrupts cardiolipin formation and causes heart muscle weakness, skeletal muscle weakness and low white blood cell counts. FDA's accelerated approval in September 2025 was based on improved knee-extensor muscle strength, a measure considered reasonably likely to predict clinical benefit. The manufacturer is required to run a confirmatory randomized, placebo-controlled trial. The approval applies to patients weighing at least 30 kg.
• Primary mitochondrial myopathy: A large phase 3 trial in adults with inherited mitochondrial muscle disease did not meet its primary endpoints.
• Heart failure, kidney injury and eye disease: Earlier-phase studies explored these areas with mixed or preliminary results. None has led to approval.

What we do not have is evidence that SS-31 slows aging, extends lifespan or improves energy and performance in healthy adults. Observations of improved muscle and heart function in older animals are intriguing, but animal aging studies frequently fail to translate to people.

Safety and What We Know

Because elamipretide has been through formal trials, its short-term safety profile is better characterized than most peptides'. The most commonly reported problems in trials were injection-site reactions, which were frequent. Other effects have been reported, and the full labeled safety information applies to the approved product in its approved population.

Important gaps remain:

• No long-term data in healthy people using it off-label
• Limited information on interactions with other mitochondrial-targeted compounds such as MOTS-c or NAD+ precursors
• Uncertainty about whether chronic use in people without mitochondrial disease offers any benefit at all

Where SS-31 Fits in a Longevity Conversation

In my practice, I start with labs and a careful look at the factors that most reliably affect mitochondrial health: aerobic fitness, resistance training, sleep, metabolic health and medication review. Several common drugs and conditions affect mitochondrial function, and addressing them is often more productive than adding a new compound.

For a patient interested in mitochondrial approaches, a reasonable conversation covers:

• What their fatigue or performance concern actually stems from, after a full evaluation
• The strongest evidence-based options, starting with exercise, as described in The Role of Mitochondrial Health in Aging
• The honest status of SS-31: approved for one rare disease, investigational for everything else
• Whether any prescription use outside the labeled indication is appropriate, which in most cases it is not

Any medication decision is individualized and made only after evaluation and labs. I do not provide or endorse generic dosing protocols for off-label or investigational use. You can review the SS-31 entry in our peptide library for a concise summary.

The Bottom Line

SS-31 is one of the more scientifically serious mitochondrial peptides. It has a clear mechanism, a real clinical development program and, as of September 2025, an FDA approval for Barth syndrome. That approval is narrow. For healthy adults interested in longevity, the evidence remains preclinical, and the foundations of mitochondrial health still come first. At Laeeq M.D., we will walk through that distinction with you clearly.

Sources

• US Food and Drug Administration. "FDA Grants Accelerated Approval to First Treatment for Barth Syndrome." FDA, September 19, 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
• Barth Syndrome Foundation. "FDA Approves First Medication for Barth Syndrome." 2025. https://www.barthsyndrome.org/article/2025/09/19/fda-approves-first-medication-for-barth-syndrome

Book a Consultation

If you are curious about mitochondrial health or have persistent fatigue, a proper evaluation is the right first step. You can book a consultation with Dr. Laeeq for a 60-minute visit, virtual or in person in Reston, VA, to review your labs, history and evidence-based options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.